{
    "guideline_id": "2024CSCO儿童及青少年淋巴瘤诊疗指南 .txt",
    "cancer_info": {
        "cancer_name": "Child and Adolescent Lymphoma"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Lymphoblastic lymphoma, low-risk group",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "VDLP induction → CAM consolidation → maintenance with 6-MP and MTX",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Lymphoblastic lymphoma, high-risk group",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Intensified Block (ifosfamide/cytarabine) ± allogeneic transplantation",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Hodgkin lymphoma, low-risk group",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "AVPC×3 ± radiotherapy (21Gy)",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Hodgkin lymphoma, low-risk group",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "VAMP×4 ± radiotherapy",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Hodgkin lymphoma, high-risk group",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "BYAVEPC×5",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Hodgkin lymphoma, high-risk group",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "OEPA×2 → COPDAC×4 ± radiotherapy",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Burkitt lymphoma, CNS-negative",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "COPAD → high-dose MTX (3-5g/m²)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Burkitt lymphoma, CNS-positive",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Intensified CYVE regimen + intrathecal therapy, without cranial radiotherapy",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Anaplastic large cell lymphoma, low-risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "BFM90 regimen (short-course chemotherapy)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Anaplastic large cell lymphoma, high-risk or relapse",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Brentuximab vedotin, crizotinib, or allogeneic transplantation",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "ALK",
                    "status": "Positive",
                    "testing_guidance": ""
                }
            ],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": ""
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Predicts prognosis; for example, ALK fusion in ALCL indicates better prognosis, EBV-EBER in HL indicates poor prognosis, MYC rearrangement in BL is diagnostic, and TEL-AML1 fusion in LBL indicates favorable outcome."
    },
    "tcm_recommendations": []
}